12.07.2018
BB BIOTECH AG CH0038389992
DGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results
BB Biotech AG reports preliminary results for 1H 2018
12-Jul-2018 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Media Release, July 12, 2018
BB Biotech AG reports preliminary results for 1H 2018
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN
CH0038389992) is releasing the following information about its results for
the first half year of 2018.
Based on preliminary unaudited consolidated results, BB Biotech closed the
first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit
in the corresponding period of the previous year). As an investment company,
the result reflects the performance of the stocks it holds in its investment
portfolio.
BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the
corresponding period.
The interim report as of June 30, 2018 will be published on July 20, 2018.
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 00
Dr. Silvia Schanz, [email protected]
Maria-Grazia Iten-Alderuccio, [email protected]
Claude Mikkelsen, [email protected]
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 07
Tanja Chicherio, [email protected]
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology
and is one of the world's largest investors in this sector. BB Biotech is
listed in Switzerland, Germany and Italy. Its investments are focused on
listed companies that are developing and commercializing novel medical
treatments and cures. BB Biotech's investment selection process is guided by
the fundamental research and analysis of physicians and molecular
biologists. Its Board of Directors has many years of experience in industry
and science.
---------------------------------------------------------------------------
12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; SIX
End of Announcement DGAP News Service
---------------------------------------------------------------------------
703867 12-Jul-2018 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
BB BIOTECH AG ISIN: CH0038389992 können Sie bei EQS abrufen
Biotechnologie , A0NFN3 , BBZA , XETR:BBZA